ClinicalTrials.gg
TerminatedNCT03366103Updated Oct 17, 2023Results posted

Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors

A Phase 1/2 interventional study of Navitoclax and Vistusertib in Metastatic Malignant Solid Neoplasm, Recurrent Lung Small Cell Carcinoma and Recurrent Malignant Solid Neoplasm, sponsored by National Cancer Institute (NCI). Terminated at 14 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-17.

Sponsored by National Cancer Institute (NCI) · Phase 1/2, Interventional, and Treatment

How we know

Why this study was terminated
Drug supply issues

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 124 studies in Neoplasm Metastasis by National Cancer Institute (NCI) — 18 open to participants now, 43 under way, none of them phase 3. Neoplasm Metastasis · National Cancer Institute (NCI).

Enrollment
87th of 112
15 · median 37
Started
2018
with 7 others
Phase 1/2
18 of 124
none open now
Registered
85th of 124
by date

Among the 124 studies in Neoplasm Metastasis by National Cancer Institute (NCI), this one is the 87th largest by enrollment of the 112 interventional ones that give a count, is one of 8 that started in 2018, is one of 18 in phase 1/2, and was the 85th registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 893 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

18 of the 124 studies in Neoplasm Metastasis by National Cancer Institute (NCI) are open now, in 3 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 18 open studies →

Who these studies take

Of the 693 Neoplasm Metastasis studies recruiting now, 541 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 124 studies in Neoplasm Metastasis by National Cancer Institute (NCI), or all of them as a file.
02

Study summary

This phase I/II trial studies the best dose and side effects of navitoclax and how well it works when given together with vistusertib in treating patients with small cell lung cancer and solid tumors that have come back (relapsed). Drugs used in chemotherapy, such as navitoclax, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Vistusertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving navitoclax and vistusertib may work better than navitoclax alone in treating patients with small cell lung cancer and solid tumors.

Read the detailed description

PRIMARY OBJECTIVES:

I. To evaluate the safety and tolerability of the combination of navitoclax and vistusertib in patients with advanced solid tumors. (Phase I) II. To determine the maximum tolerated dose (MTD), dose limiting toxicities (DLT), and recommended phase 2 doses (RP2D) of navitoclax and vistusertib. (Phase I) III. To determine the objective response rate (ORR), defined as complete plus partial response, of the combination of navitoclax and vistusertib in patients with recurrent small cell lung cancer (SCLC). (Phase II)

SECONDARY OBJECTIVES:

I. To evaluate the pharmacokinetics of navitoclax and vistusertib when administered together. (Phase I) II. To observe and record anti-tumor activity. (Phase I) III. To confirm the safety and tolerability of navitoclax and vistusertib at the RP2D. (Phase II) IV. To estimate progression free survival (PFS) and overall survival (OS) of the combination of navitoclax and vistusertib at the RP2D. (Phase II) V. To estimate disease control rate (DCR) of the combination of navitoclax and vistusertib at the RP2D. (Phase II)

CORRELATIVE OBJECTIVES:

I. To assess pharmacodynamic changes in levels of phosphorylated 4EBP1 (p4EBP1) the ratio of p4EBP1 to total (p4EBP1/4EBP1) in paired pre-treatment and on-treatment biopsies at the RP2D. (Phase II) II. To correlate changes in BAX and MCL-1 with response. (Phase II) III. To estimate the baseline inter-patient variability in p4EBP1, pS6, BAX, and MCL-1. (Phase II) IV. To explore exposure-response relationships between navitoclax and vistusertib exposure and the pharmacodynamic endpoints (safety, efficacy, and laboratory correlatives). (Phase II)

OUTLINE: This is a phase I, dose-escalation study followed by a phase II study.

Patients receive navitoclax orally (PO) once daily (QD) and vistusertib PO twice daily (BID) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 30 days and then every 8-12 weeks for up to 2 years.

03

Conditions studied

  • Metastatic Malignant Solid Neoplasm
  • Recurrent Lung Small Cell Carcinoma
  • Recurrent Malignant Solid Neoplasm
  • Refractory Malignant Solid Neoplasm
  • Stage III Lung Small Cell Carcinoma, by American Joint Committee on Cancer (AJCC) v7
  • Stage IIIA Lung Small Cell Carcinoma AJCC v7
  • Stage IIIB Lung Small Cell Carcinoma AJCC v7
  • Stage IV Lung Small Cell Carcinoma AJCC v7
  • Unresectable Solid Neoplasm
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • PHASE 1 SPECIFIC ELIGIBILITY CRITERIA
  • Patients must have or cytologically confirmed that is or unresectable and for which standard curative or palliative measures do not exist or are no longer effective
  • PHASE 2 SPECIFIC ELIGIBILITY CRITERIA
  • Patients must have histologically or cytologically confirmed small cell lung cancer whose disease has or progressed after >= 1 prior therapy, one of which must have been a platinum doublet; pathology confirmation must be done at Sidney Kimmel Comprehensive Cancer Center (SKCCC) or at the local participating site
  • Patients must have , defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >= 20 mm (>= 2 cm) by chest x-ray or as >= 10 mm (>= 1 cm) with computed tomography (CT) scan, magnetic resonance imaging (MRI), or calipers by clinical exam
  • Subjects must be willing to undergo 2 sets of core needle (pre-treatment and on-treatment), if there are lesions amenable to biopsy; an optional core biopsy will be requested at progression
  • GENERAL ELIGIBILITY CRITERIA
  • (ECOG) performance status =\< 1 ( >= 70%)
  • of greater than 12 weeks
  • Leukocytes >= 3,000/mcL
  • >= 1,500/mcL
  • >= 9.0 g/dL
  • >= 100,000/mcL
  • (aPTT), prothrombin time (PT) =\< 1.2 x (ULN)
  • Total =\< 1.5 x ULN (patients with Gilbert's syndrome may have serum bilirubin > 1.5 ULN)
  • (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =\< 2.5 x institutional ULN if no demonstrable liver metastases or =\< 5 x ULN in the presence of liver metastases
  • Creatinine =\< 1.5 x ULN and concurrent (CrCl) >= 50 mL/min/1.73 m\^2 for patients with creatinine (Cr) > 1.5 x ULN
  • Proteinuria \< 1+ on dipstick testing (if 2+ seen on first test, retest >= 24 hours later)
  • Patients with a history of central nervous system (CNS) metastases must have documentation of stable or improved status based on brain imaging for at least 2 weeks after completion of definitive treatment and within 2 weeks prior to first dose of study drug, off or on a stable dose of
  • Patients must have completed chemotherapy, biological or radiotherapy >= 3 weeks prior to entering the study
  • Patients must have recovered to =\< grade 1 adverse events or to =\< grade 2 alopecia and sensory neuropathy due to prior treatment
  • Patients must be able to understand and the willingness to sign a written document
  • Patients must be able to swallow pills
  • The effects of navitoclax and vistusertib on the developing human fetus are unknown; for this reason, women of and men must agree to use adequate prior to study entry, for the duration of study participation, and up to 90 days following completion of therapy; for women this should include one highly effective method of contraception and one barrier method as defined below

    • Highly effective methods include:

      • Total abstinence from sexual intercourse (minimum one complete menstrual cycle prior to study drug administration);
      • Vasectomized partner;
      • Medroxyprogesterone acetate depot injection;
      • Placement of a copper-banded intrauterine device (IUD) or intrauterine system (IUS);
      • Bilateral tubal ligation;
    • Barrier methods include:

      • Condom;
      • Occlusive cap (e.g. diaphragm or cervical/vault caps) with spermicide
    • Please note: use of other oral, injected or implanted hormonal methods of contraception cannot be considered highly effective as it is currently unknown whether vistusertib may reduce their effectiveness; periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception
    • Additionally, male subjects (including those who are vasectomized) whose partners are pregnant or might be pregnant must agree to use condoms for the duration of the study and for 90 days following completion of therapy
  • Women of childbearing potential must have a negative urine pregnancy test within 7 days prior to initiation of treatment, women will be considered not of childbearing potential if they are surgically sterile (bilateral oophorectomy or hysterectomy) and/or (amenorrheic for at least 12 months)
  • Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and for 90 days after completion of navitoclax and/or vistusertib administration

Exclusion criteria

Exclusion Criteria:

  • PHASE 2 SPECIFIC EXCLUSION CRITERIA
  • Prior treatment with a TORC1, dual TORC1/2 inhibitor, or BCL-2/xL inhibitor
  • Patients with active other than SCLC or patients with prior curatively treated malignancy at high risk of relapse during the study period with the exception of localized squamous or basal cell skin cancers
  • PHASE 1 AND GENERAL EXCLUSION CRITERIA
  • Major surgery within 21 days of starting protocol treatment
  • Patients who are receiving any other agents
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to navitoclax or vistusertib
  • Patients receiving anticoagulation or anti- therapy are excluded due to the risk of thrombocytopenia with navitoclax

    • Excluded agents include heparin or low molecular weight heparin, warfarin, clopidogrel, ibuprofen and other non-steroidal anti-inflammatory drugs (NSAIDS), tirofiban, and other anticoagulants, drugs, or herbal supplements that affect platelet function
    • Administration of heparin to keep subject's infusion lines patent is allowed; low-dose anticoagulation medications that are used to maintain the patency of a central intravenous catheter are allowed
    • Aspirin will not be allowed within 7 days prior to the first dose of navitoclax or during navitoclax administration; however, subjects who have previously received aspirin therapy for thrombosis prevention, may resume a low dose (i.e., maximum 100 mg once daily [QD]) of aspirin if platelet counts are stable (>= 50,000/mm3) through 6 weeks of navitoclax administration
    • All decisions regarding treatment with aspirin therapy will be determined by the investigator in conjunction with the medical monitor
  • Patients with an underlying condition predisposing them to bleeding or currently exhibiting signs of bleeding
  • Patients with a recent history of non-chemotherapy-induced thrombocytopenic-associated bleeding within 1 year prior to the first dose of study drug
  • Patients with a significant history of cardiovascular disease or procedures within the preceding 6 months (e.g., myocardial infarction [MI], coronary artery bypass graft placement, angioplasty, vascular stent, angina pectoris, ventricular arrhythmias requiring continuous therapy, congestive heart failure [NYHA] grade >= 2, thrombotic or thromboembolic event)
  • Any of the following cardiac criteria:

    • Mean resting interval (QTc using Fridericia's formula [QTcF]) > 470 msec obtained from 3
    • Congenital or family history of long or short QT syndrome, Brugada syndrome, known history of QTc prolongation or torsades de pointes within 12 months of entering the study
    • Abnormal echocardiogram at baseline ( [LVEF] \< 40% and shortening fraction [SF] \< 15%)
  • Drugs which have an increased risk for QTc prolongation should be avoided
  • Patients with uncontrolled type 1 or type 2 diabetes. Vistusertib belongs to a class of drugs that causes hyperglycemia. In order to assess toxicity, patients with an elevated risk of hyperglycemia should be excluded from study
  • Patients currently receiving medications or herbal supplements of the classes below are ineligible; patients are eligible if they stop use of these compounds at least 1 week prior to receiving any treatment on this protocol

    • Potent inhibitors or inducers of /5 (CYP3A4 inhibitors such as ketoconazole and clarithromycin are not allowed 7 days prior to the first dose of navitoclax and during navitoclax administration)
    • Strong or moderate inhibitors of Pgp or BRCP1
    • Sensitive substrates of CYP2C9 (i.e. phenytoin and warfarin)
    • Substrates of certain drug transporters (OATP1B1, OATP1B3, MATE1 or MATE2K)
  • Pregnant women are excluded from this study because navitoclax and vistusertib have the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with navitoclax and vistusertib breastfeeding should be discontinued if the mother is treated with navitoclax and vistusertib
  • Patients positive for (HIV) are not excluded from this study, but HIV-positive patients must have:

    • A stable regimen of highly active anti-retroviral therapy (HAART) that does not include strong or moderate CYP3A4 inducers or inhibitors
    • No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections
    • A above 250 cells/mcL and an undetectable HIV viral load on standard polymerase chain reaction (PCR)-based test
  • Any hematopoietic growth factors (e.g., filgrastim [granulocyte colony-stimulating factor; G-CSF], sargramostim [granulocyte-macrophage colony-stimulating factor; GM-CSF]) within 14 days prior to receiving study treatment
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Patients who have received a live, attenuated vaccines within 4 weeks of first dose of drug
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Treatment (navitoclax, vistusertib)

    Patients receive navitoclax PO QD and vistusertib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

    Biological: Navitoclax · Drug: Vistusertib

Interventions

  • BiologicalNavitoclax

    Given PO

    Also known as: A-855071.0, ABT-263, BcI-2 Family Protein Inhibitor ABT-263

  • Given PO

    Also known as: AZD 2014, AZD-2014, AZD2014

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose Limiting Toxicities (Phase I)

    Graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4.0. The number of participants with dose limiting toxicities at each dose level will be reported with exact binomial 95% confidence intervals. All patients who receive at least 1 dose of both study drugs, regardless of their eligibility for the study, will be evaluable for toxicity.

    Time frame: Up to 30 days after last treatment, an average of 3 months

  2. Overall Response Rate (ORR) (Phase II)

    Defined as Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. partial response or complete response, of the combination in patients with recurrent small cell lung cancer. The ORR will be reported with its corresponding 95% confidence interval.

    Time frame: Up to 1.5 years

Secondary outcomes

  1. Occurrence of a Bi-directional Pharmacokinetic (PK) Interaction

    Concentrations of each study agent present in the blood at the specified time point are reported for each study agent.

    Time frame: Through Day 15

  2. Number of Participants Experiencing Adverse Events by Grade (Phase II)

    Graded by NCI CTCAE v 4.0. The number of participants with toxicities by grade in the phase 2 study will be reported with exact binomial 95% confidence intervals.

    Time frame: Up to 1.5 years

  3. Progression Free Survival (PFS) (Phase II)

    Based on RECIST 1.1. Standard life table methods will be used to analyze PFS. We will report the one-year and median PFS with 95% confidence intervals.

    Time frame: Up to 1.5 years

  4. Overall Survival (OS) at Year 1 (Phase II)

    Standard life table methods will be used to analyze OS. We will report the one-year and median OS with 95% confidence intervals.

    Time frame: At Year 1

  5. Disease Control Rate (Phase II)

    Based on RECIST 1.1. The proportion of patients achieving disease control will be reported with exact 95% binomial confidence intervals.

    Time frame: Up to 1.5 years

Other outcomes

  1. Change in p4EBP1 Expression

    Descriptive statistics and box plots with jittered data points will be used to visualize all raw data. Will be assessed with paired t-tests.

    Time frame: Baseline up to 1.5 years

  2. Change in Ratio p4EBP1/4EBP1

    Descriptive statistics and box plots with jittered data points will be used to visualize all raw data. Will be assessed with paired t-tests.

    Time frame: Baseline up to 1.5 years

  3. Change in Ratio pS6/S6

    Descriptive statistics and box plots with jittered data points will be used to visualize all raw data. Will be assessed with paired t-tests.

    Time frame: Baseline up to 1.5 years

  4. Change in BAX and MCl-1 Expression

    Descriptive statistics and box plots with jittered data points will be used to visualize all raw data. Will be assessed with paired t-tests.

    Time frame: Baseline up to 1.5 years

  5. Pharmacodynamic Parameters

    Exploratory correlative studies with pharmacodynamic (biological endpoints, toxicity and efficacy) will be analyzed using nonparametric statistics.

    Time frame: Up to 1.5 years

07

Results

Posted May 3, 2023
Limitations and caveats
Only 1 participant was enrolled to Phase 2 before the study was closed to accrual for low accrual.

Participant flow

Phase 1: 03/20/2018 - 11/11/2019 Phase 2: 7/29/2020 - 5/19/2021

Participant flow — Overall Study
MilestonePhase 1 - Dose Level 1Phase 1 - Dose Level 2Phase 2
Started951
Completed631
Not completed320
Withdrew: Disease progression310
Withdrew: Adverse event010

Outcome measures

PrimaryNumber of Participants With Dose Limiting Toxicities (Phase I)

Graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4.0. The number of participants with dose limiting toxicities at each dose level will be reported with exact binomial 95% confidence intervals. All patients who receive at least 1 dose of both study drugs, regardless of their eligibility for the study, will be evaluable for toxicity.

Time frame:
Up to 30 days after last treatment, an average of 3 months
Reported as:
Count of participants · Participants
Number of Participants With Dose Limiting Toxicities (Phase I)
ParticipantsPhase 1 - Dose Level 1Phase 1 - Dose Level 2
DLT02
No DLT61
PrimaryOverall Response Rate (ORR) (Phase II)

Defined as Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. partial response or complete response, of the combination in patients with recurrent small cell lung cancer. The ORR will be reported with its corresponding 95% confidence interval.

Time frame:
Up to 1.5 years
Reported as:
Count of participants · Participants
Overall Response Rate (ORR) (Phase II)
ParticipantsPhase 2
Partial Response (PR) or Complete Response (CR)0
Stable Disease (SD)0
Progression (PD)1
SecondaryOccurrence of a Bi-directional Pharmacokinetic (PK) Interaction

Concentrations of each study agent present in the blood at the specified time point are reported for each study agent.

Time frame:
Through Day 15
Reported as:
Mean · ng/ml
Occurrence of a Bi-directional Pharmacokinetic (PK) Interaction
ng/mlNavitoclax 150 mg + Vistusertib 35 mgNavitoclax 250 mg + Vistusertib 35 mgNavitoclax 250 mg Reduced to 150 mg + Vistusertib 35 mg
Navitoclax average of individual steady-state trough concentration (avg Cmin,ss)1145 ± 2891966 ± 9992283
Navitoclax Cycle 1 Day 1 Concentration 6 hours after dose (C6h)1808 ± 9803254 ± 1233—
Navitoclax Cycle 1 Day 15 Concentration 6 hours after dose (C6h)2260 ± 9932830 ± 11903450
Navitoclax Cycle 1 Day 15 maximum concentration (Cmax)2393 ± 9133060 ± 10703910
Vistusertib average of individual steady-state trough concentration (avg Cmin,ss)211 ± 207559 ± 550238.5
Vistusertib Cycle 1 Day 1 Concentration 2 hours after dose (C2h)372 ± 266419 ± 108—
Vistusertib Cycle 1 Day 15 Concentration 2 hours after dose (C2h)1061 ± 6751032 ± 832273
SecondaryNumber of Participants Experiencing Adverse Events by Grade (Phase II)

Graded by NCI CTCAE v 4.0. The number of participants with toxicities by grade in the phase 2 study will be reported with exact binomial 95% confidence intervals.

Time frame:
Up to 1.5 years
Reported as:
Number · participants
Number of Participants Experiencing Adverse Events by Grade (Phase II)
participantsPhase 2
Grade 1 Adverse Events1
Grade 2 Adverse Events1
Grade 3 Adverse Events0
Grade 4 Adverse Events0
Grade 5 Adverse Events0
SecondaryProgression Free Survival (PFS) (Phase II)

Based on RECIST 1.1. Standard life table methods will be used to analyze PFS. We will report the one-year and median PFS with 95% confidence intervals.

Time frame:
Up to 1.5 years
Reported as:
Count of participants · Participants
Progression Free Survival (PFS) (Phase II)
ParticipantsPhase 2
Progression Free Survival (PFS) (Phase II)0
SecondaryOverall Survival (OS) at Year 1 (Phase II)

Standard life table methods will be used to analyze OS. We will report the one-year and median OS with 95% confidence intervals.

Time frame:
At Year 1
Reported as:
Count of participants · Participants
Overall Survival (OS) at Year 1 (Phase II)
ParticipantsPhase 2
Overall Survival (OS) at Year 1 (Phase II)0
SecondaryDisease Control Rate (Phase II)

Based on RECIST 1.1. The proportion of patients achieving disease control will be reported with exact 95% binomial confidence intervals.

Time frame:
Up to 1.5 years
Reported as:
Count of participants · Participants
Disease Control Rate (Phase II)
ParticipantsPhase 2
Disease Control Rate (Phase II)0
Other pre-specifiedChange in p4EBP1 Expression

Descriptive statistics and box plots with jittered data points will be used to visualize all raw data. Will be assessed with paired t-tests.

Time frame:
Baseline up to 1.5 years

No measurements were reported for this outcome.

Other pre-specifiedChange in Ratio p4EBP1/4EBP1

Descriptive statistics and box plots with jittered data points will be used to visualize all raw data. Will be assessed with paired t-tests.

Time frame:
Baseline up to 1.5 years

No measurements were reported for this outcome.

Other pre-specifiedChange in Ratio pS6/S6

Descriptive statistics and box plots with jittered data points will be used to visualize all raw data. Will be assessed with paired t-tests.

Time frame:
Baseline up to 1.5 years

No measurements were reported for this outcome.

Other pre-specifiedChange in BAX and MCl-1 Expression

Descriptive statistics and box plots with jittered data points will be used to visualize all raw data. Will be assessed with paired t-tests.

Time frame:
Baseline up to 1.5 years

No measurements were reported for this outcome.

Other pre-specifiedPharmacodynamic Parameters

Exploratory correlative studies with pharmacodynamic (biological endpoints, toxicity and efficacy) will be analyzed using nonparametric statistics.

Time frame:
Up to 1.5 years

No measurements were reported for this outcome.

Adverse events

Collected over Up to 1.5 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1 - Dose Level 16/9 (66.7%)2/9 (22.2%)9/9 (100%)
Phase 1 - Dose Level 23/5 (60%)2/5 (40%)5/5 (100%)
Phase 21/1 (100%)0/1 (0%)1/1 (100%)
Most frequent serious events
Most frequent serious events
EventPhase 1 - Dose Level 1Phase 1 - Dose Level 2Phase 2
Pleural effusionRespiratory, thoracic and mediastinal disorders0/92/50/1
DyspneaRespiratory, thoracic and mediastinal disorders0/91/50/1
HypokalemiaMetabolism and nutrition disorders0/91/50/1
DiarrheaGastrointestinal disorders0/91/50/1
HypoxiaRespiratory, thoracic and mediastinal disorders0/91/50/1
Colonic obstructionGastrointestinal disorders1/90/50/1
Enterocolitis infectiousInfections and infestations1/90/50/1
Platelet count decreasedInvestigations1/90/50/1
Blood bilirubin decreasedInvestigations1/90/50/1
Most frequent other events
Showing 10 of 69
Most frequent other events
EventPhase 1 - Dose Level 1Phase 1 - Dose Level 2Phase 2
DiarrheaGastrointestinal disorders4/92/51/1
NauseaGastrointestinal disorders3/93/51/1
Abdominal PainGastrointestinal disorders2/91/51/1
DyspepsiaGastrointestinal disorders1/90/51/1
Non-cardiac chest painGeneral disorders1/90/51/1
AnorexiaMetabolism and nutrition disorders1/93/51/1
PruritusSkin and subcutaneous tissue disorders1/90/51/1
Renal and urinary disordersRenal and urinary disorders0/90/51/1
Skin disorderSkin and subcutaneous tissue disorders0/90/51/1
Cognitive disturbanceNervous system disorders0/90/51/1

Baseline characteristics

Age, Continuous
Age, Continuous(years)Phase 1 - Dose Level 1Phase 1 - Dose Level 2Phase 2Total
Median49 (35 to 74)67 (53 to 71)77 (77 to 77)60 (35 to 77)
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1 - Dose Level 1Phase 1 - Dose Level 2Phase 2Total
Female6309
Male3216
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase 1 - Dose Level 1Phase 1 - Dose Level 2Phase 2Total
Hispanic or Latino0000
Not Hispanic or Latino85114
Unknown or Not Reported1001
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase 1 - Dose Level 1Phase 1 - Dose Level 2Phase 2Total
American Indian or Alaska Native0000
Asian0101
Native Hawaiian or Other Pacific Islander0000
Black or African American1001
White74112
More than one race0000
Unknown or Not Reported1001
Region of Enrollment
Region of Enrollment(participants)Phase 1 - Dose Level 1Phase 1 - Dose Level 2Phase 2Total
United States95115
Weight
Weight(kg)Phase 1 - Dose Level 1Phase 1 - Dose Level 2Phase 2Total
Median75 (58.5 to 86.8)68.5 (56.6 to 114.4)86.2 (86.2 to 86.2)75 (56.6 to 114.4)
Height
Height(cm)Phase 1 - Dose Level 1Phase 1 - Dose Level 2Phase 2Total
Median167.6 (162.6 to 188.0)165.0 (162.5 to 178.0)172.7 (172.7 to 172.7)167.6 (162.5 to 188)
Body Surface Area (BSA)
Body Surface Area (BSA)(m^2)Phase 1 - Dose Level 1Phase 1 - Dose Level 2Phase 2Total
Median1.90 (1.63 to 2.00)1.76 (1.62 to 2.31)2.03 (2.03 to 2.03)1.9 (1.62 to 2.31)

2 further baseline measures are reported on the registry.

08

Study locations

14 sites
  • Los Angeles County-USC Medical Center
    Los Angeles, California 90033, United States
  • USC / Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
  • Johns Hopkins University/Sidney Kimmel Cancer Center
    Baltimore, Maryland 21287, United States
  • Massachusetts General Hospital Cancer Center
    Boston, Massachusetts 02114, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Memorial Sloan Kettering Basking Ridge
    Basking Ridge, New Jersey 07920, United States
  • Memorial Sloan Kettering Monmouth
    Middletown, New Jersey 07748, United States
  • Memorial Sloan Kettering Bergen
    Montvale, New Jersey 07645, United States
  • Memorial Sloan Kettering Commack
    Commack, New York 11725, United States
  • Memorial Sloan Kettering Westchester
    Harrison, New York 10604, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Memorial Sloan Kettering Nassau
    Uniondale, New York 11553, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2018 to primary completion in Jul 2021, 40 months.

Results were first posted in May 2023, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2017
First posted
Dec 8, 2017
StartActual
Mar 20, 2018
Primary completionActual
Jul 28, 2021
CompletionActual
Sep 21, 2022
Results first posted
May 3, 2023
Last update
Oct 17, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03366103
Responsible party
Sponsor
First posted
Dec 8, 2017
Start date
Mar 20, 2018
Primary completion
Jul 28, 2021
Completion
Sep 21, 2022
Results posted
May 3, 2023
Last update
Oct 17, 2023

Study contacts

Christine L Hann
principal investigator · JHU Sidney Kimmel Comprehensive Cancer Center LAO

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Navitoclax · Vistusertib

Start the discussion